Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWIDJK)

• Drug Name: FORMESTANE Drug Info
• Synonyms: formestane; 566-48-3; 4-Hydroxyandrost-4-ene-3,17-dione; 4-Hydroxyandrostenedione; Lentaron; CGP-32349; Lentaron(R); 4-OH-A; B, Aromatase inhibitor; 4-Hydroxy-4-androstene-3,17-dione; NSC 282175; 17-dione; 4-OHA; CGP 32349; Formestane [INN:BAN]; UNII-PUB9T8T355; CCRIS 7483; ANDROST-4-ENE-3,17-DIONE, 4-HYDROXY-; 4-Hydroxy-delta(sub 4)-androstenedione; BRN 1889793; MLS002153359; MLS000028826; PUB9T8T355; CHEBI:75172

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Withdrawn from market	[1]

• Cross-matching ID:
  PubChem CID: 11273
  ChEBI ID: CHEMBL132530
  CAS Number: CAS 566-48-3
  TTD Drug ID: DMWIDJK

Molecule-Related Drug Atlas

Drug(s) Targeting Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anastrozole	DMNP60F	Breast cancer	2C60-2C65	Approved	[5]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[6]
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[6]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[7]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[8]
Testolactone	DMVY4GN	Breast cancer	2C60-2C65	Approved	[9]
LIAROZOLE	DM4OYXE	Dermatological disease	DA24.Y	Phase 2/3	[10]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[11]
BGS-649	DMO4MNQ	Endometriosis	GA10	Phase 2	[12]
NARINGENIN	DMHAZLM	N. A.	N. A.	Phase 1	[10]

Drug(s) Affected By Adenylate kinase isoenzyme 1 (AK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[4]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[4]
Anastrozole	DMNP60F	Breast cancer	2C60-2C65	Approved	[4]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[4]
Selenium	DM25CGV	N. A.	N. A.	Approved	[13]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[15]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[16]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[16]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[17]

Drug(s) Affected By 17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[18]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[20]
Metyrapone	DMI7FVQ	Cushing disease	5A70	Approved	[21]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[22]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[23]
Dutasteride	DMQ4TJK	Benign prostatic hyperplasia	GA90	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[25]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[23]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aromatase (CYP19A1)	TTSZLWK	CP19A_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1)	OT6EBDHM	DHB1_HUMAN	Gene/Protein Processing	[3]
Adenylate kinase isoenzyme 1 (AK1)	OT614AR3	KAD1_HUMAN	Drug Response	[4]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] The taiwaniaquinoids: a review. J Nat Prod. 2010 Feb 26;73(2):284-98.
• [3] Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol. 2005 Apr;94(5):461-7.
• [4] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [5] Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
• [6] Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
• [7] Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
• [8] Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
• [9] Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
• [10] Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
• [11] Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032111)
• [13] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [14] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [15] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [16] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [17] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [18] Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
• [19] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [20] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [21] The H295R system for evaluation of endocrine-disrupting effects. Ecotoxicol Environ Saf. 2006 Nov;65(3):293-305.
• [22] Organotin compounds enhance 17beta-hydroxysteroid dehydrogenase type I activity in human choriocarcinoma JAr cells: potential promotion of 17beta-estradiol biosynthesis in human placenta. Biochem Pharmacol. 2006 Apr 28;71(9):1349-57.
• [23] Estrogenic endocrine disruptive components interfere with calcium handling and differentiation of human trophoblast cells. J Cell Biochem. 2003 Jul 1;89(4):755-70.
• [24] Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs. 2007 Oct;25(5):491-7.
• [25] Acetaminophen Modulates the Expression of Steroidogenesis-Associated Genes and Estradiol Levels in Human Placental JEG-3 Cells. Toxicol Sci. 2021 Jan 6;179(1):44-52. doi: 10.1093/toxsci/kfaa160.
• [26] Decreased levels of H3K9ac and H3K27ac in the promotor region of ovarian P450 aromatase mediated low estradiol synthesis in female offspring rats induced by prenatal nicotine exposure as well as in human granulosa cells after nicotine treatment. Food Chem Toxicol. 2019 Jun;128:256-266. doi: 10.1016/j.fct.2019.03.055. Epub 2019 Apr 6.